Cysview Disease Interactions
There are 3 disease interactions with Cysview (hexaminolevulinate).
Hexaminolevulinate (applies to Cysview) cystitis
Major Potential Hazard, High plausibility.
Inflammation of the bladder may interfere with the diagnostic utility of hexaminolevulinate, which is an ester of the heme precursor, aminolevulinic acid. Following intravesical instillation of hexaminolevulinate, photoactive porphyrins are formed and accumulate intracellularly in bladder wall lesions. In humans, a higher degree of accumulation of porphyrins has been demonstrated in neoplastic or inflamed cells compared to normal bladder urothelium. As such, inflammation may lead to increased porphyrin buildup and higher risk of local toxicity upon illumination as well as false-positive fluorescence. Hexaminolevulinate should not be used in patients at high risk of bladder inflammation, such as those who received BCG immunotherapy or intravesical chemotherapy within the past 90 days. Widespread inflammation of the bladder should be excluded by cystoscopy before hexaminolevulinate is administered. If a widespread inflammation in the bladder becomes evident during white light inspection, the blue light inspection should be avoided.
Hexaminolevulinate (applies to Cysview) hematuria
Major Potential Hazard, High plausibility.
The use of hexaminolevulinate is contraindicated in patients with gross hematuria. The presence of blood within the bladder may interfere with the detection of tissue fluorescence.
Hexaminolevulinate (applies to Cysview) porphyria
Major Potential Hazard, High plausibility.
The use of hexaminolevulinate is contraindicated in patients with a diagnosis or a family history of porphyria. Hexaminolevulinate is an ester of the heme precursor, aminolevulinic acid. Following intravesical instillation, photoactive porphyrins are formed and accumulate intracellularly in bladder wall lesions.
Cysview drug interactions
There are 2 drug interactions with Cysview (hexaminolevulinate).
Report options
More about Cysview (hexaminolevulinate)
- Cysview consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: malignancy photosensitizers
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.